P.0391 Ultra-resistant major depression: treatment with in-esketamine on compassionate use

2021 ◽  
Vol 53 ◽  
pp. S281
Author(s):  
A.I. De Santiago-Díaz ◽  
M. Gómez-Revuelta ◽  
J. Sastre-Yañez ◽  
E. Gómez-Ruiz ◽  
J. Artal-Simón
Keyword(s):  
Major Depression ◽  
Depression Treatment ◽  
Compassionate Use

Predictors of Recovery From Major Depression Among Geriatric Psychiatry Inpatients: The Importance of Caregivers' Beliefs

1999 ◽  
Vol 11 (2) ◽  
pp. 149-157 ◽  
Author(s):  
Robin J. Casten ◽  
Barry W. Rovner ◽  
Yochi Shmuely-Dulitzki ◽  
Rona E. Pasternak ◽  
Rodney Pelchat ◽  
...  
Keyword(s):  
Depressive Symptoms ◽  
Major Depression ◽  
Multivariate Analyses ◽  
Geriatric Psychiatry ◽  
Depression Treatment ◽  
Electroconvulsive Treatment ◽  
Caregiver Support ◽  
Important Relationship ◽  
Dsm Iv ◽  
Course Of Depression

Caregiver support is an important factor in recovery from depression among older patients. We examined whether caregivers' perceptions regarding patients' ability to control depressive symptoms were related to depression recovery. Depression treatment, demographics, number of depressive symptoms, and health were controlled. The sample comprised 51 geriatric psychiatry inpatients who met DSM-IV criteria for major depression and who had a primary caregiver. Depression was assessed at both admission and discharge. Caregivers were asked to indicate whether they believed their patient-relatives could control their depressive symptoms. At discharge, 33 patients (64.7%) were “remitted” and 18 (35.3%) were “nonremitted.” Multivariate analyses indicated that receiving electroconvulsive treatment, having fewer depressive symptoms caregivers perceived to be within patient control, and being female predicted depression remission at discharge. This study highlights the important relationship between family dynamics and course of depression.

scholarly journals Quality of depression treatment in Black Americans with major depression and comorbid medical illness

2014 ◽  
Vol 36 (4) ◽  
pp. 431-436 ◽  
Author(s):  
Amma A. Agyemang ◽  
Briana Mezuk ◽  
Paul Perrin ◽  
Bruce Rybarczyk
Keyword(s):  
Major Depression ◽  
Black Americans ◽  
Depression Treatment ◽  
Medical Illness

scholarly journals Major depression, depression treatment and quality of primary medical care

2008 ◽  
Vol 30 (1) ◽  
pp. 20-25 ◽  
Author(s):  
Benjamin G. Druss ◽  
Kimberly Rask ◽  
Wayne J. Katon
Keyword(s):  
Major Depression ◽  
Medical Care ◽  
Depression Treatment ◽  
Primary Medical Care

scholarly journals hs-CRP Predicts Improvement in Depression in Patients With Type 1 Diabetes and Major Depression Undergoing Depression Treatment: Results From the Diabetes and Depression (DAD) Study

Diabetes Care ◽  
2016 ◽  
Vol 39 (10) ◽  
pp. e171-e173 ◽  
Author(s):  
Daniela Zahn ◽  
Stephan Herpertz ◽  
Christian Albus ◽  
Norbert Hermanns ◽  
Christoph Hiemke ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Major Depression ◽  
Depression Treatment ◽  
Treatment Results ◽  
Hs Crp

scholarly journals The Impact of Parity on Major Depression Treatment Quality in the Federal Employees??? Health Benefits Program After Parity Implementation

Medical Care ◽  
2006 ◽  
Vol 44 (6) ◽  
pp. 506-512 ◽  
Author(s):  
Alisa B. Busch ◽  
Haiden A. Huskamp ◽  
Sharon-Lise T. Normand ◽  
Alexander S. Young ◽  
Howard Goldman ◽  
...  
Keyword(s):  
Major Depression ◽  
Health Benefits ◽  
Treatment Quality ◽  
Depression Treatment ◽  
Federal Employees ◽  
The Impact

scholarly journals The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review

2018 ◽  
Vol 19 (8) ◽  
pp. 2410 ◽  
Author(s):  
Gianluca Serafini ◽  
Giulia Adavastro ◽  
Giovanna Canepa ◽  
Domenico De Berardis ◽  
Alessandro Valchera ◽  
...  
Keyword(s):  
Major Depression ◽  
Suicidal Behavior ◽  
Depression Treatment ◽  
Treatment Resistant Depression ◽  
Long Term Effects ◽  
Treatment Resistant ◽  
Refractory Depression ◽  
Research Findings ◽  
Resistant Depression

Although several pharmacological options to treat depression are currently available, approximately one third of patients who receive antidepressant medications do not respond adequately or achieve a complete remission. Thus, novel strategies are needed to successfully address those who did not respond, or partially respond, to available antidepressant pharmacotherapy. Research findings revealed that the opioid system is significantly involved in the regulation of mood and incentives salience and may be an appropriate target for novel therapeutic agents. The present study aimed to systematically review the current literature about the use of buprenorphine (BUP) for major depression, treatment-resistant depression (TRD), non-suicidal self-injury (NSSI) behavior, and suicidal behavior. We investigated Pubmed and Scopus databases using the following keywords: “buprenorphine AND depression”, “buprenorphine AND treatment resistant depression”, “buprenorphine AND suicid*”, “buprenorphine AND refractory depression”. Several evidence demonstrate that, at low doses, BUP is an efficacious, well-tolerated, and safe option in reducing depressive symptoms, serious suicidal ideation, and NSSI, even in patients with TRD. However, more studies are needed to evaluate the long-term effects, and relative efficacy of specific combinations (e.g., BUP + samidorphan (BUP/SAM), BUP + naloxone (BUP/NAL), BUP + naltrexone) over BUP monotherapy or adjunctive BUP treatment with standard antidepressants, as well as to obtain more uniform guidance about the optimal BUP dosing interval.

scholarly journals Determination of oxidative stress parameters in fluoxetine users

2020 ◽  
Vol 8 (5) ◽  
pp. 172-182
Author(s):  
Magda Susana Perassolo ◽  
Juliana Raquel Raach ◽  
Tainara Gomes Vargas ◽  
Andressa Schmidt dos Santos ◽  
Natália Alves Silva ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Major Depression ◽  
Control Group ◽  
Depression Treatment ◽  
First Line ◽  
Antioxidant Power ◽  
Oxidative Stress Parameters ◽  
Daily Dose ◽  
Total Antioxidant

Fluoxetine (FLU), a selective serotonin reuptake inhibitor, is the first line in depression treatment and it is involved in oxidative stress (OE). Thus, this study aimed to analyze the OE parameters in patients diagnosed with depression and treated with FLU. Were evaluated 121 volunteers divided into two groups: 58 fluoxetine users (with major depression) and 63 non-fluoxetine users (control group, without major depression). The OE was evaluated by determining the levels of malondialdehyde (MDA), total antioxidant power (FRAP) and activity of antioxidant enzymes glutathione peroxidase (GPx) and superoxide dismutase (SOD). MDA, FRAP, GPx and SOD were dosed in plasma. The influence of age, smoking, alcoholism, comorbidities, use of another drugs and antioxidants in the OE were evaluated. The results were compared between the groups. In relation to the fluoxetine daily dose, MDA presented higher levels in patients using 20 mg daily FLU when compared to the control group, as well as the activity of the GPx enzyme and the FRAP levels. In this way, the use of fluoxetine may interfere with the OE parameters, causing an increase in OE levels.

scholarly journals Relationship between personality and psychopathology in a longitudinal community study: a test of the predisposition model

2016 ◽  
Vol 46 (8) ◽  
pp. 1693-1705 ◽  
Author(s):  
M. P. Hengartner ◽  
V. Ajdacic-Gross ◽  
C. Wyss ◽  
J. Angst ◽  
W. Rössler
Keyword(s):  
Major Depression ◽  
Mental Disorders ◽  
Personality Assessment ◽  
Odds Ratio ◽  
Common Mental Disorders ◽  
Community Study ◽  
Depression Treatment ◽  
Structured Interviews ◽  
Prognostic Information ◽  
Treatment Use

BackgroundMounting evidence supports the notion that personality is crucial in the aetiopathology of common mental disorders, but studies that allow for aetiological conclusions are lacking. The aim of the present study was thus to provide a test of the predisposition model.MethodWe analysed data from the Zurich Cohort Study, a 30-year longitudinal epidemiological community study of an adult cohort (n = 591) from 1979 to 2008. Personality was assessed in 1988 with an established personality questionnaire, and psychopathology through seven semi-structured interviews between 1979 and 2008.ResultsOn the basis of personality assessment from 1988, used as predictor of subsequent psychopathology (1993–2008), while adjusting for sex and prior mental disorders (1979–1988), neuroticism related significantly with future major depression episodes [odds ratio (OR) = 1.41], anxiety disorders (OR = 1.32) and depression treatment use (OR = 1.41). When participants with a past 10-year history (i.e. 1979–1988) of either major depression, anxiety disorder or depression treatment use were excluded, neuroticism in 1988 still significantly predicted first incidence (i.e. 1993–2008) of major depression episodes (OR = 1.53) and depression treatment use (OR = 1.84).ConclusionsThe present study provides compelling evidence that the personality trait of neuroticism constitutes an independent risk factor for subsequent major depression episodes and use of respective professional treatments, which serves as a proxy for particularly severe and impairing depression episodes. We therefore advocate that personality traits could provide clinically useful prognostic information when considered carefully.

Sign in / Sign up

Export Citation Format

Share Document